The present invention relates to N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives having the general formula I ##STR00001## wherein n is 0, 1, 2 or 3; R.sub.1 and R.sub.2 are independently H, (C.sub.1-4)alkyl or (C.sub.1-4)alkyloxy; R.sub.3 is (C.sub.3-8)alkyl, (C.sub.4-7)cycloalkyl, (C.sub.4-7)cycloalkyl (C.sub.1-3)alkyl, (C.sub.6-12)aryl(C.sub.1-3)alkyl (wherein the aryl moiety is optionally substituted with 1 3 substituents selected from (C.sub.1-4)alkyl, (C.sub.1-4)alkyloxy, halogen, trifluoromethyl and methoxycarbonyl), or (C.sub.4-9)heteroaryl(C.sub.1-3)alkyl; or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising said derivatives, and to the use of these N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives in the treatment of disorders or conditions which are responsive to inhibition of the GlyT-2 transporter, such as muscle spasticity, epilepsy and, particularly, acute, chronic and neuropathic pain.